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Abstract: Acute low back pain (LBP) is one of the most prevalent diseases worldwide. Since there is
evidence of excessive prescriptions of analgesics, i.e., opioids, the aim of this study was to describe
the use of pain medications in patients with LBP in the Swiss primary care setting. A retrospective,
observational study was performed using medical prescriptions of 180 general practitioners (GP) dur-
ing years 2009–2020. Patterns of pain medications (nonsteroidal anti-inflammatory drugs (NSAIDs),
paracetamol, and opioids) as well as co-medications were analyzed in patients with a LBP diagnosis.
Univariable and multivariable regression analyses assessed GP and patient characteristics associated
with the prescription of pain medication. Patients included were 10,331 (mean age 51.7 years, 51.2%
female); 6449 (62.4%) received at least one pain medication and of these 86% receive NSAIDs and 22%
opioids. GP characteristics (i.e., self-employment status) and patient characteristics (male gender and
number of consultations) were associated with significantly higher odds of receiving any pain medica-
tion in multivariable analysis. 3719 patients (36%) received co-medications. Proton-pump-inhibitors
and muscle relaxants were the most commonly used co-medications. In conclusion, two-thirds of
LBP patients were treated with pain medications. Prescribing patterns were conservative, with little
use of strong opioids and co-medications.
Keywords: low back pain; pain medication; NSAID; opioid; primary care
1. Introduction
Low back pain (LBP) is one of the most prevalent diseases worldwide [1]. The lifetime
prevalence of LBP in developed countries is up to 80% [2–5] and a systematic review
calculated the incidence ranged between 0.024 and 7.0% [6]. In Switzerland 43% of the
population report an episode of LBP within the last four weeks [4] and back pain ranked
second in patient reported reasons for physician consultations [7].
Despite the often self-limiting and benign character of LBP [4,8], the individual burden
in some patients can be high and many patients still receive supportive therapies [9]. Key
driver for a treatment is the intention to reduce the individual burden and to prevent
chronicity. The patterns of pharmacological treatment are of interest and numerous na-
tional and international treatment recommendations or guidelines have been developed
to provide high quality of care in pharmacological patient treatment. However, there
is a considerable degree of disagreement between the different recommendations [10]
and guideline adherence varies [3,9,11]. Therefore, prescribing patterns vary between the
different countries and different health care settings [9,12–14]. Of particular interest is the
use of opioids in non-cancer patients, as their use is associated with increased rates of
side effects like dependence or substance abuse, as seen in the “opioid-crisis”, in North
America [15,16].
The focus of this study was the prescription of pain medications for the treatment of
LBP in the Swiss primary care sector. In particular, we aimed to determine the number of
patients with LBP treated with at least one pain medication and to examine the patterns
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of prescriptions. We sought to determine prescriber and patient characteristics associated
with higher odds of receiving pain medication. Finally, we aimed to determine frequencies
and patterns of prescribed co-medications in the treatment of acute LBP.
2. Materials and Methods
2.1. Study Design and Database
This observational study was retrospective. Data were extracted from the FIRE (Family
medicine ICPC Research using Electronic medical records) database. The database, since
2009, collects routine medical data from around 500 General practitioners (GPs), around
10% of all GPs in the German-speaking area of Switzerland. Currently it holds records of
>780,000 patients and >9.4 million consultations.
2.2. Inclusion Criteria
The study period was 2009–2020. According to the current International Classification of
Primary Care 2 (ICPC-2) diagnosis code system LBP was defined as: (1) L86-Back syndrome
with radiating pain; (2) L84-Back syndrome without radiating pain; (3) L03-Low back symp-
tom/complaint. All patients ≥ 18 years with a LBP diagnosis and at least one consultation
within the twelve months (baseline period) prior to the LBP diagnosis (Figure 1) were in-
cluded. Then they were followed-up for six months after diagnosis. Only the first episode
of LBP and all consultations from the day of diagnosis were considered. For the analysis of
pain medications and co-medications, patients with specific ICPC-2 codes, which would
independently qualify for a pain medication (for example cancer or trauma patients) were
excluded (full list in Supplementary Material).
 
–
for “Low back symptom complaint” and “Back syndrome without radiating pain”) were 
Figure 1. Flowchart. FIRE: Family medicine ICPC Research using Electronic medical records;
n: number of patients; w/o: without; #: ICPC2 LBP diagnosis codes: L03, L84, L86; *: Pain medication
of interest: non-steroidal anti-inflammatory drugs, paracetamol and opioids; +: Full list of all
excluded ICPC2 diagnosis codes in Supplementary Material.
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2.3. Study Variables
Pain medications of interest were nonsteroidal anti-inflammatory drugs (NSAIDs),
paracetamol, and opioids. Prescription patterns were described in terms of percentages of
patients with one or more prescriptions. Time of prescriptions was defined as a continuous
variable (in month unit) or categorized in two ways, as necessary: (1) before diagnosis, at
diagnosis, within week 1 after diagnosis, within week 2–4 after diagnosis, later than four
weeks after diagnosis; (2) before diagnosis, at diagnosis, 0–2 months after the diagnosis,
2–6 months after the diagnosis.
To determine patient and prescriber characteristics associated with prescriptions, we
used the following characteristics: patient related (age at diagnosis ≤ or > 50 years, sex,
number of consultations after diagnosis, LBP syndrome groups, or diagnosis code) and GP
related (sex, age: continuous or binary with cut-off 55 years, years of experience in practice,
type of practice, type and level of employment, self-dispensing of drugs). Type of practice
was defined as: single, double or group practice. Type of employment categories were:
self-employed or employee. Level of employment was defined as: <50%, between 50 and
79%, between 80 and 99% and 100%. Drug dispensing was considered as a possible factor
that might influence prescriptions at GP level. In fact in some regions of Switzerland, GPs
are allowed to dispense drugs, but not in others, therefore the variable drug dispensing
was defined as yes or no.
Co-medications of interest were: proton-pump-inhibitors (PPI), antidepressants, sleep-
ing pills, and muscle relaxants. All medications were analyzed using the Anatomical
Therapeutic Chemical Classification System (ATC) codes. All ATC codes are provided in
Supplementary Material.
2.4. Statistical Analysis
Summary statistics were reported as means (standard deviation, SD) and range (min–
max), median (interquartile range, IQR) or number (percentage, %) as appropriate. In
descriptive tables prescription patterns were compared between the LBP syndrome groups
using one-way ANOVA test and chi-square test, with/without simulated p-values, as
appropriate. Patients with code combinations (for example patients with simultaneous
codes for “Low back symptom/complaint” and “Back syndrome without radiating pain”)
were excluded for group comparisons. Analogously, co-medications use was also compared
between these groups.
Prescription rates of pain medications were represented graphically with the density
(frequency distribution of prescribed pain medications in density scale) and cumulative
(cumulative frequency of prescribed pain medications) functions. Counts of prescriptions
per patient, overall and stratified by LBP groups, were modelled through Poisson regression
models corrected for repeated measurements within patients. Results were presented as
risk ratio (RR) (95% confidence interval (CI)).
Univariable and multivariable mixed-effects logistic regression analyses were per-
formed to assess the association of GP and patient determinants with any pain medication
prescription and, as separate analyses, any NSAIDs, opioids and Paracetamol prescriptions.
A stratified analysis by LBP groups was also performed. Mixed models were used to
account for the correlation of patients within GP and were performed for any and specific
prescriptions. In univariable analysis, every effect was considered separately in a single
model. In multivariable analysis, relevant characteristics were considered together. Multi-
variable models were developed starting from variables with p ≤ 0.2 in univariable analysis
and then implementing a stepwise backward elimination to include all relevant factors
which better fit the models. Missing observations were removed from the analysis. Results
of regression analyses were presented as odds ratio (OR) (95% CI) with indication of the
number of non-missing observations, in terms of patients and GP. Intra-class correlation
(ICC) was also reported in multivariable analysis. For all tests, p ≤ 0.05 was considered
statistically significant. All analyses were carried out using statistical package R version
3.6.1. (https://www.R-project.org, accessed on 25 March 2021).
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2.5. Ethics
Research using the FIRE database did not need ethical approval, as the project did
not fall under the scope of the Federal Act on Research involving Human Beings (Human
Research Act) (BASEC-Nr: Req-2017-0079).
3. Results
3.1. Basic Characteristics
We included 10,331 patients (Figure 1). 5289 (51.2%) patients were female. The mean
age was 51.7 years (range: 18–100 years). A number of 8222 patients (80%) had a diagnosis
code of non-radiating back pain (L03 or L84 plus 94 patients with a combination of L03
and L84). On average, each patient had 2.1 consultations (median: one consultation (IQR:
1.00, 2.00)). Between groups, a significant difference was found in the distribution of con-
sultations, age, and sex. In particular, patients with radiating pain were significantly older
and had, on average, more consultations compared to patients in the diagnostic groups
with non-radiating pain. Furthermore, comparing the patients with a back syndrome with
radiating and without radiating pain, we found a higher proportion of female patients in
the group with radiating pain. (Table 1).



























<0.001male, n (%) 5042 (48.8) 835 (47.5) 1271 (51.6) 2709 (47.8) 227 (51.0)
female, n (%) 5289 (51.2) 923 (52.5) 1194 (48.4) 2954 (52.2) 218 (49.0)
1 Of the 445 patients with combinations, there were 94 patients with combinations of back syndrome without radiating pain and with
symptom/complaint. 2 SD: standard deviation. Bold: Significant results are presented in bold.
3.2. Prescribing Patterns
Patterns of prescribed pain medications were presented in Table 2: 62.4% (6449 pa-
tients) received at least one pain medication and 25.4% (2623 patients) received two or
more pain medications. Of the patients with at least one pain medication, the proportion of
patients receiving NSAIDs, paracetamol, and opioids was 86% (5545 patients), 39.4% (2544),
and 22% (1417), respectively. The most commonly used NSAID was diclofenac (2502 pre-
scriptions), and the most commonly prescribed opioid was tramadol (1180 prescriptions).
A complete list of prescribed pain medications was provided in Table S1, Supplementary
Material. Patients with an opioid therapy had in most cases a concurrent therapy with a
NSAID and/or paracetamol (87.4%) and seldom opioids alone (12.6%). There were signifi-
cantly fewer pain medication prescriptions in the group “Low back symptom/complaint”
compared to the group “Back syndrome without radiating pain “(p < 0.001) (Table 2).
Among patients with medication, 1.84 pain medications were prescribed on average. We
found no relevant difference in the number of pain medications prescribed in dependence
of the time of prescription (Table S2, Supplementary Material).
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n 1 = 10,331 n = 1758 n = 2465 n = 5663 n = 445
A—Basic prescribing patterns 2 n (%) n (%) n (%) n (%) n (%)
Patients without any pain medication 3882 (37.6) 588 (33.4) 814 (33.0) 2360 (41.7) 120 (27.0) <0.001
Patients with at least one pain medication 6449 (62.4) 1170 (66.6) 1651 (67.0) 3303 (58.3) 325 (73.0) <0.001
Patients with one pain medication 3826 (37.0) 614 (34.9) 1071 (75.7) 1992 (35.2) 149 (33.5) <0.001
Patients with two or more pain medications 2623 (25.4) 556 (31.6) 580 (23.5) 1311 (23.2) 176 (39.6) <0.001
Patients in which the first prescribed pain medication
after or at diagnosis was
NSAID 2813 (27.2) 465 (26.5) 813 (33.0) 1408 (24.9) 127 (28.5) <0.001
Opioid 505 (4.9) 132 (7.5) 104 (4.2) 221 (3.9) 48 (10.8) <0.001
Paracetamol 853 (8.3) 118 (6.7) 153 (6.2) 528 (9.3) 54 (12.1) <0.001
B—Specific prescribing patterns 3
NSAID
Patients receiving NSAIDs 5545 (86.0) 1014 (86.7) 1478 (89.5) 2779 (84.1) 274 (84.3) <0.001
Patients receiving only NSAIDs 3088 (47.9) 514 (43.9) 966 (58.5) 1509 (45.7) 99 (30.5) <0.001
Opioids
Patients receiving opioids 1417 (22.0) 367 (31.4) 278 (16.8) 652 (19.7) 120 (36.9) <0.001
Patients receiving only opioids 178 (2.8) 44 (3.8) 38 (2.3) 81 (2.5) 15 (4.6) 0.033
Paracetamol
Patients receiving paracetamol 2544 (39.4) 441 (37.7) 512 (31.0) 1439 (43.6) 152 (46.8) <0.001
Patients receiving only paracetamol 602 (9.3) 89 (7.6) 115 (7.0) 372 (11.3) 26 (8.0) <0.001
Combination therapies
Patients receiving NSAIDs and paracetamol 1342 (20.8) 200 (17.1) 292 (17.7) 770 (23.3) 80 (24.6) <0.001
Patients receiving NSAIDs and opioids 639 (9.9) 171 (14.6) 135 (8.2) 274 (8.3) 59 (18.2) <0.001
Patients receiving NSAIDs, opioids and paracetamol 476 (7.4) 129 (11.0) 85 (5.1) 226 (6.8) 36 (11.1) <0.001
Patients receiving opioids and paracetamol 124 (1.9) 23 (2.0) 20 (1.2) 71 (2.1) 10 (3.1) 0.068
C—Timing 4
Time from diagnosis to first NSAID prescription 8.71 (30.11) 8.38 (28.82) 8.53 (30.59) 8.76 (29.95) 10.41 (33.59) 0.966
Time from diagnosis to first Opioid prescription 7.53 (25.14) 6.61 (21.95) 7.51 (26.45) 6.24 (23.11) 16.04 (36.31) 0.903
Time from diagnosis to first paracetamol prescription 13.13 (37.13) 11.78 (33.68) 14.80 (36.27) 13.42 (38.84) 8.56 (29.23) 0.807
1 n = number of patients; NSAIDs: non-steroidal anti-inflammatory drugs. 2 Table part A shows basic prescribing patterns. Values are presented as absolute numbers and percentage. Percentage values refer to
the overall patients analyzed. 3 Table part B shows specific prescribing patterns of the drug classes of interest. Values are presented as absolute numbers and percentage. Percentages values refer to the amount of
patients receiving any drug. Combination therapies with tramadol and paracetamol are counted only once in the opioid group. 4 Table part C shows time (in days) from diagnosis to first prescription in patient
groups in which the pain medication was used as first line therapy. Values are presented as mean (SD). Bold: Significant results are presented in bold.
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3.3. Time Patterns of Prescriptions
During the baseline period, we observed a consistent rate of prescriptions, and nearly
50% of NSAIDs were prescribed before diagnosis (Figure 2, cumulative function). After the
peak at time of diagnosis, pain medication prescriptions, still elevated in the follow up period,
declined back to the level of prescribing during the baseline period (Figure 2—density function
and Table S3, Supplementary Material). In patients with only pain medications at or after
the diagnosis, the average of the time from diagnosis to the first NSAID, paracetamol, or
opioid prescription was 9, 13 and 8 days, respectively (Table 2, part C). However, in this
group the majority of pain medications were prescribed at the day of diagnosis (median 0.0,
(IQR: 0.00, 0.00) for all groups). Prescribing patterns in patients with multiple prescriptions
of one or different classes is shown in Table S4, Supplementary Material. In patients with a
NSAID/opioid co-medication, the first opioid prescription in this group was on average 9
days after the first NSAID.
–
– –
Figure 2. Time pattern of prescriptions: This figure shows the time pattern of pain medication
prescriptions in 6449 patients during baseline and follow up period, in months. Primary y-axis:
histogram in scale density (density function, lower curves) and its smoothed curve for each pain
medication class. It describes the proportion of prescriptions occurring in that time period. Secondary
y-axis: cumulative proportion (cumulative function, upper curves) of all pain medication prescrip-
tions over time. It describes the total prescription rate up to the time period. NSAIDs: non-steroidal
anti-inflammatory drugs.
The models of the number of prescriptions per patient, overall and by LBP diagnosis
groups were reported in Table S5, Supplementary Material. After correcting for the type
of medication, patients with Low back symptom/complaint and prescriptions after two
months from the diagnosis had a higher risk of getting more prescriptions, compared to the
ones who got prescriptions at diagnosis (RR = 1.06, 95% CI: 1.01–1.11, p = 0.017). Moreover,
after correcting for time of prescriptions, in all LBP subgroups Opioids and Paracetamol
have a lower incidence rate compared to NSAIDS.
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3.4. Regression Analysis: GP and Patient Characteristics Association
Associations between patient and GP characteristics on pain medication prescription
(any pain medication and by pain medication subgroup) are shown in Table 3. Additional
regression analysis, univariable and multivariable, stratified by LBP diagnosis group was
reported in Table S6, Supplementary Material. We identified both GP (self-employment
and non-self-dispensing status) and patient characteristics (male gender and number of
consultations) which were associated with significantly higher odds of receiving any pain
medication in multivariable analysis. In subgroup analysis for each pain medication class
we found that, after correcting for other confounding factors, patient age > 50 years, at the
time of diagnosis, was significantly associated with increased odds of prescribing NSAIDs
(OR: 1.24, 95%CI: 1.13–1.36, p < 0.001), but decreased odds of prescribing opioids (OR: 0.66,
95%CI: 0.58–0.76, p < 0.001) or paracetamol (OR: 0.84, 95%CI: 0.75–0.93, p = 0.001).
Table 3. Association between patient and GP characteristics (predictors) and pain medication prescription (binary outcome):
mixed-effects logistic regression analysis, accounting for correlation within GP.





OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GP characteristics
Age 1 (continuous) n = 9825, GP = 161 0.99 (0.98, 1.01) 0.195 0.98 (0.96, 0.99) 0.007
0.97 (0.95, 0.99) <0.001
Age (age ≤ 55) 1.07 (0.90, 1.26) 0.450 1.00 (0.83, 1.20) 0.988
0.84 (0.66, 1.06) 0.132
Male gender (female) n = 10252, GP = 178 1.67 (1.11, 2.5) 0.014 1.86 (1.25, 2.77) 0.002 1.38 (0.92, 2.07) 0.118 1.27 (0.88, 1.85) 0.206




n = 10331, GP = 180 1.13 (0.40, 3.19) 0.820 1.27 (0.46, 3.51) 0.647 1.35 (0.54, 3.34) 0.521 1.10 (0.45, 2.65) 0.838
Group practice 1.25 (0.67, 2.35) 0.487 1.19 (0.64, 2.20) 0.579 1.00 (0.57, 1.76) 1.000 1.12 (0.66, 1.92) 0.668
Years in practice n = 9731, GP = 148 0.99 (0.98, 1.01) 0.431 0.99 (0.98, 1.01) 0.882 0.98 (0.97, 1.00) 0.050 0.99 (0.97, 1.00) 0.077
0.98 (0.96, 1.00) 0.012
Self-Employed
(employee)
n = 9978, GP = 161 3.03 (2.04, 4.51) <0.001 3.13 (2.13, 4.60) <0.001 2.59 (1.67, 4.03) <0.001 1.71 (1.16, 2.52) 0.007
2.36 (1.64, 3.40) <0.001 2.38 (1.63, 3.47) <0.001 2.34 (1.50, 3.63) <0.001 1.56 (1.07, 2.28) 0.020
Employment level
(100%) <50%
n = 8938, GP = 143 0.41 (0.20, 0.84) 0.016 0.52 (0.26, 1.06) 0.073 0.42 (0.19, 0.91) 0.028 0.57 (0.29, 1.11) 0.098
50–79% 0.55 (0.34, 0.87) 0.010 0.56 (0.36, 0.88) 0.013 0.59 (0.37, 0.94) 0.025 0.72 (0.48, 1.08) 0.113
80–99% 0.82 (0.51, 1.34) 0.437 0.90 (0.56, 1.44) 0.666 0.70 (0.44, 1.11) 0.132 0.95 (0.63, 1.45) 0.822
Self-dispensing (yes) No n = 10311, GP = 175 1.98 (1.29, 3.05) 0.002 2.00 (1.32, 3.04) 0.001 1.21 (0.83, 1.78) 0.315 1.44 (0.97, 2.14) 0.070
1.76 (1.22, 2.52) 0.002 1.79 (1.26, 2.55) 0.001
Patient characteristics
Age at diagnosis > 50
(≤50) years old
n = 10331, GP = 180 0.83 (0.76, 0.91) <0.001 1.11 (1.01, 1.21) 0.024 0.52 (0.46, 0.59) <0.001 0.72 (0.65, 0.79) <0.001
1.24 (1.13, 1.36) <0.001 0.66 (0.58, 0.76) <0.001 0.84 (0.75, 0.93) 0.001
Male gender (female) n = 10331, GP = 180 1.07 (0.97, 1.16) 0.167 1.17 (1.08, 1.28) <0.001 0.99 (0.88, 1.12) 0.912 0.79 (0.72, 0.87) <0.001




n = 10331, GP = 180 2.21 (2.05 2.39) <0.001 1.24 (1.2 1.27) <0.001 1.24 (1.22, 1.27) <0.001 1.24 (1.21, 1.27) <0.001






n = 9886, GP = 179 0.88 (0.76, 1.01) 0.065 0.92 (0.81, 1.06) 0.257 0.92 (0.81, 1.06) 0.257 0.81 (0.70, 0.94) 0.005
Back syndrome without
radiating pain
1 (0.86, 1.17) 0.964 1.03 (0.89, 1.19) 0.726 1.03 (0.89, 1.19) 0.726 0.86 (0.74, 1.02) 0.076
Results for the univariable analysis were in the corresponding upper row and results for multivariable analysis in the corresponding
lower row (grey shaded). If the predictor was not considered in multivariable analysis, the fields are blank. For multivariable analysis,
the following numbers apply depending on the endpoint: 1: All prescriptions: n = 9958, GP = 156, ICC = 0.14, 2: NSAID prescriptions:
N = 9958, GP = 156, ICC = 0.13; 3: Opioids: n = 9798, GP = 156, ICC = 0.13; 4: Paracetamol: n = 9696, GP = 146, ICC = 0.11. GP: general
practitioner; OR: odds ratio; CI: confidence interval; n: number of patients; ICC: intra-class correlation coefficient. 1 Age of GP was defined
as continuous or binary variable according to computational requirements. 2 Excluding patients with combined diagnosis. Bold: Significant
results are presented in bold.
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3.5. Co-Medications
3719 patients (36% of 10,331 patients) received one or more co-medications of in-
terest and had no other ICPC-2 diagnosis codes, which would qualify for one of the co-
medications (Table S7, Supplementary Material). Patients with a radiating pain had more
co-medications compared to the other groups (45.5% vs. 35.4%, and 35.7%, respectively
p < 0.001). Of all patients, the co-medications prescribed were: 12.7% (muscle relaxants), 7%
(antidepressants), 6.4% (sleeping pills), and 22.4% (PPI), respectively, with pantoprazole
and tizanidine the most commonly used drugs. Only one-third (31.7%) of patients with a
NSAID therapy had a co-medication with a PPI.
4. Discussion
In this study, we determined frequencies and patterns of pain medication prescriptions
in patients with LBP in Swiss primary care. Only two-thirds of all patients with an ICPC-2
diagnosis code of LBP were managed with any kind of pain medication therapy and if a
pain medication was prescribed, in 86% of these cases at least a NSAID was prescribed.
However, opioids were prescribed in one-fifth of all patients.
4.1. Pattern of Prescriptions
Nearly two-thirds of all patients in our cohort received at least one pain medication,
with diclofenac, ibuprofen, and paracetamol being the most commonly used drugs. This
proportion is similar to pain medication prescription rates from studies conducted in
the US or The Netherlands [11,17]. However, there are considerable differences in the
type of pain medication used. In our analysis, only 22% received opioids, with tramadol
the most commonly used opioid. This is in contrast to the US, where recent studies,
using health claims data or medical health records data, suggest that opioids are the most
commonly used pain medications for LBP [11] or that nearly two-thirds of patients with a
LBP diagnosis had taken opioids in the year before/after the diagnosis [18]. Opioid use is
much more common in the US and Canada than in the European or Asian countries and per
capita consumption has risen in the last years [19]. Most guidelines on LBP recommend the
use of opioids only if non-opioids treatments have failed, as opioid use is associated with
increased risk of dependency. A recent review found a pooled incidence of 4.7% for opioid
dependency in patients treated with opioid for non-cancer pain [20]. In addition, opioid
therapy in LBP patients is associated with increased odds of chronic work loss [21] and
disability [22]. The proportion of patients receiving opioids in our cohort is still high, but
two facts support a prudent use of opioids in the Swiss primary care setting. First, in our
cohort, only 12.6% of patients with opioids lack a basic non-opioid pain therapy and second,
tramadol, a weak opioid, was by far the most commonly prescribed opioid. This is in
contrast to the data obtained in the US, where especially the use of strong narcotic opioids
predominates the pain management [11]. However, we found that opioid treatment in our
cohort was more common in patients ≤ 50 years of age. However, if opioids are prescribed
in elderly patients, GPs should be aware of the higher risks of opioid associated side effects
in this patient group [23] due to the higher prevalence of polypharmacy or comorbidities.
In real life, however, there is a difference between pain medication prescribed and
pain medication taken by the patients. Back pain is one of the most common reasons for
taking over the counter (OTC) pain medication [24]. Due to their free availability, ingestion
mainly concerns the pain medications of the NSAID group and paracetamol. The pain
medication taken in real life are therefore likely to be higher than those calculated in this
study. In addition, there seems to be evidence, that not only quantity is affected by OTC
medications, but also quality. For example in one study analyzing analgesic use in older
adults with LBP, paracetamol appears to be obtained directly much more frequently than
NSAIDs [25].
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4.2. Time Pattern of the Prescriptions during Baseline and Follow-Up Period
Pain medications are recommended in acute LBP [26] and in accordance with the
guidelines, we found a peak of pain medication prescriptions at time of diagnosis and the
elevated level of pain medication consumption in the follow up period declined back to the
level of prescribing during the baseline period. In addition, our observation, that NSAID
prescriptions took place earlier in the course of LBP compared with opioids, are in line
with many current recommendations [10,17,27–30] and confirm the overall restrictive use
of opioids in Swiss Primary Care.
4.3. Association with Pain Medication Prescriptions
We identified both patient and GP characteristics associated with increased odds of
pain medication prescriptions. To our knowledge, there are no studies analyzing specific
patient or GP characteristics associated with prescribing patterns for acute LBP in the
outpatient setting. However, pain in general is a strong predictor for the use of healthcare
services [31]. For patients with chronic LBP in the primary care setting, it was reported that
men, especially those with a high number of consultations, have not only a high number
of prescribed medications but also higher opioid doses [18]. This supports our finding
that the number of consultations is related to the odds of prescribing pain medications.
We found that the odds of prescribing any pain medication are significantly higher if the
physicians did not self-dispense drugs. This finding is surprising as studies report that the
status of self-dispensing is associated with increased frequencies of drug prescribing [32].
4.4. Co-Medications and LBP
One third of the patients, 36%, received co-medications: proton-pump-inhibitors
and muscle relaxants were the most commonly used. Co-medication use, especially
the use of muscle relaxants or antidepressants, is common among patients with LBP
and their use is mentioned in many guidelines [10,26]. In contrast to the US, the use of
both muscle relaxants and antidepressants is less common in our cohort [11,17]. Muscle
relaxants are used twice as much as antidepressants, according to the current evidence
favoring muscle relaxants over antidepressants [26,33], for which evidence is limited [34].
In contrast to muscle relaxants or antidepressants, sleeping pills are not mentioned in the
guidelines. The association between pain and sleep disturbances is well described [35]
and one study reported that, approximately, two-thirds of the patient with LBP suffers
from sleeping disturbances [36]. However, sleeping pills were rarely prescribed in our
cohort: we found a low rate of PPI prescriptions in patients with concurrent NSAID therapy.
PPI are recommended in many guidelines to prevent NSAID associated gastrointestinal
bleedings [37] but data on the dose and duration of NSAID treatments would be necessary
to finally judge the appropriateness of this finding.
4.5. Limitations and Strengths
The study has some limitations. First, we cannot exclude specific pain medication
prescriptions for a reason other than an acute LBP episode (i.e., alternative pain, or prescrip-
tion of pain medications as a fever-reducing medication). This is because ATC codes do not
depend on ICPC-2 code in FIRE database. Therefore, our approach was conservative and
all patients with ICPC-2 diagnosis codes, qualifying for a pain medication beside the LBP
diagnosis, (i.e., all cancer or trauma diagnosis) were excluded. Moreover, a long baseline
period of twelve months minimized the chance of missing a diagnosis qualifying for a
pain medication. Second, we could only analyze the first LBP episode for each patient.
Due to the different structures of medical software used by conducting GPs, we could
not definitely exclude cases where diagnosis codes were reported along the subsequent
patient consultations, even if the reason of encounter was for other complaints. Finally,
we could not exclude the possibility that patients take additional OTC pain medications,
which are not prescribed by the GP. Therefore, there is a possibility that we overestimate
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the number of patients without any pain medication and underestimate the number of
pain medication taken.
On the other hand, the main strength of this study is the large sample size of patients.
The validity of our data and consequently of our results, is supported by the fact that the
distribution of age, gender as well as the mean of the number of consultations and the
number of patients receiving any kind of pain medication, are in line with the numbers
reported in similar health care settings [9,38,39] and available national data [4].
5. Conclusions
The study described patterns of pain medication therapy in a large cohort in Swiss
primary care. More than one-third of the patients had no pain medication and 86% of the
pain medications was at least a NSAID, in line with current guidelines. However, the still
substantial use of opioids suggests that GPs have to be aware of handling of opioids in
non-cancer pain.
Supplementary Materials: The following are available online at https://www.mdpi.com/2077
-0383/10/7/1366/s1, Table S1: Detail of pain medication prescriptions in 10,331 patients with a
low back pain diagnosis, Table S2: Relative number of prescriptions per patient stratified by the
time of prescription and by diagnosis group (6449 patients), Table S3: Time of first pain medication
prescriptions in 6449 patients with low back pain, Table S4: Time patterns (in days) of pain medication
prescription in 6449 patients with a low back pain diagnosis, Table S5: Counts of prescriptions
(outcome) per patient stratified by LBP groups. Poisson regression models (multivariable analysis)
corrected for repeated measurements within patients, Table S6: Counts of prescriptions (outcome)
per patient stratified by LBP groups. Poisson regression models (multivariable analysis) corrected for
repeated measurements within patients, Table S7: Co-medications in 10,331 patients with a low back
pain diagnosis, List of all used ATC codes, List of all ICPC codes excluded.
Author Contributions: Conceptualization, A.P. and T.R.; methodology, A.P. and S.D.G.; software, G.P.
and S.D.G.; validation, A.P., S.Z. and S.D.G.; formal analysis, S.D.G.; investigation, A.P.; resources,
T.R.; data curation, G.P.; writing—original draft preparation, S.D.G., S.Z. and A.P.; writing—review
and editing, S.D.G., G.P., S.Z., T.R., A.P.; visualization, S.D.G. and G.P.; supervision, T.R.; project
administration, A.P. and S.D.G. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A
systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385, 117–171. [CrossRef]
2. Donnoli, F.; Azari, M. Transition from acute to chronic low back pain; A biopsychosocial perspective. Chiropr. J. Aust. 2013, 43,
93–98.
3. Di Iorio, D.; Henley, E.; Doughty, A. A survey of primary care physician practice patterns and adherence to acute low back
problem guidelines. Arch. Fam. Med. 2000, 9, 1015–1021. [CrossRef] [PubMed]
4. Back-Report Switzerland 2020. Rheumaliga Schweiz Juli 2020. Available online: https://www.rheumaliga.ch/assets/doc/CH_
Dokumente/blog/2020/rueckenreport-2020/Rueckenreport-2020.pdf (accessed on 25 March 2021).
5. Health Statistics 2019. Swiss Federal Statistical Office. Available online: https://www.bfs.admin.ch/bfs/en/home/statistics/
health.html (accessed on 25 March 2021).
6. Fatoye, F.; Gebrye, T.; Odeyemi, I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol.
Int. 2019, 39, 619–626. [CrossRef]
7. Finley, C.R.; Chan, D.S.; Garrison, S.; Korownyk, C.; Kolber, M.R.; Campbell, S.; Eurich, D.T.; Lindblad, A.J.; Vandermeer, B.;
Allan, G.M. What are the most common conditions in primary care? Systematic review. Can. Fam. Phys. 2018, 64, 832–840.
J. Clin. Med. 2021, 10, 1366 11 of 12
8. Pengel, L.H.; Herbert, R.D.; Maher, C.G.; Refshauge, K.M. Acute low back pain: Systematic review of its prognosis. BMJ 2003,
327, 323. [CrossRef]
9. Schers, H.; Braspenning, J.; Drijver, R.; Wensing, M.; Grol, R. Low back pain in general practice: Reported management and
reasons for not adhering to the guidelines in The Netherlands. Br. J. Gen. Pract. 2000, 50, 640–644.
10. Oliveira, C.B.; Maher, C.G.; Pinto, R.Z.; Traeger, A.C.; Lin, C.C.; Chenot, J.F.; van Tulder, M.; Koes, B.W. Clinical practice guidelines
for the management of non-specific low back pain in primary care: An updated overview. Eur. Spine J. 2018, 27, 2791–2803.
[CrossRef] [PubMed]
11. Ivanova, J.I.; Birnbaum, H.G.; Schiller, M.; Kantor, E.; Johnstone, B.M.; Swindle, R.W. Real-world practice patterns, health-care
utilization, and costs in patients with low back pain: The long road to guideline-concordant care. Spine J. 2011, 11, 622–632.
[CrossRef] [PubMed]
12. Bishop, P.B.; Wing, P.C. Knowledge transfer in family physicians managing patients with acute low back pain: A prospective
randomized control trial. Spine J. 2006, 6, 282–288. [CrossRef] [PubMed]
13. Piccoliori, G.; Engl, A.; Gatterer, D.; Sessa, E.; in der Schmitten, J.; Abholz, H.-H. Management of low back pain in general
practice—is it of acceptable quality: An observational study among 25 general practices in South Tyrol (Italy). BMC Fam. Pract.
2013, 14, 148. [CrossRef]
14. Williams, C.M.; Maher, C.G.; Hancock, M.J.; McAuley, J.H.; McLachlan, A.J.; Britt, H.; Fahridin, S.; Harrison, C.; Latimer, J. Low
back pain and best practice care: A survey of general practice physicians. Arch. Intern. Med. 2010, 170, 271–277. [CrossRef]
[PubMed]
15. Morland, R. Evolution of the national opioid crisis. Nursing 2019, 49, 51–56. [CrossRef] [PubMed]
16. Belzak, L.; Halverson, J. The opioid crisis in Canada: A national perspective. Health Promot. Chronic Dis. Prev. Can. 2018, 38,
224–233. [CrossRef] [PubMed]
17. Mens, J.M. The use of medication in low back pain. Best Pract. Res. Clin. Rheumatol. 2005, 19, 609–621. [CrossRef] [PubMed]
18. Kobus, A.M.; Smith, D.H.; Morasco, B.J.; Johnson, E.S.; Yang, X.; Petrik, A.F.; Deyo, R.A. Correlates of higher-dose opioid
medication use for low back pain in primary care. J. Pain 2012, 13, 1131–1138. [CrossRef]
19. Deyo, R.A.; Von Korff, M.; Duhrkoop, D. Opioids for low back pain. BMJ 2015, 350, g6380. [CrossRef]
20. Higgins, C.; Smith, B.H.; Matthews, K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were
exposed to opioid analgesic therapy: A systematic review and meta-analysis. Br. J. Anaesth 2018, 120, 1335–1344. [CrossRef]
21. Volinn, E.; Fargo, J.D.; Fine, P.G. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. Pain 2009,
142, 194–201. [CrossRef]
22. Ashworth, J.; Green, D.J.; Dunn, K.M.; Jordan, K.P. Opioid use among low back pain patients in primary care: Is opioid
prescription associated with disability at 6-month follow-up? Pain 2013, 154, 1038–1044. [CrossRef]
23. Chau, D.L.; Walker, V.; Pai, L.; Cho, L.M. Opiates and elderly: Use and side effects. Clin. Interv. Aging 2008, 3, 273–278. [CrossRef]
24. Wilcox, C.M.; Cryer, B.; Triadafilopoulos, G. Patterns of use and public perception of over-the-counter pain relievers: Focus on
nonsteroidal antiinflammatory drugs. J. Rheumatol. 2005, 32, 2218–2224.
25. Enthoven, W.T.M.; Scheele, J.; Bierma-Zeinstra, S.M.A.; Bueving, H.J.; Bohnen, A.M.; Peul, W.C.; van Tulder, M.W.; Berger, M.Y.;
Koes, B.W.; Luijsterburg, P.A.J. Analgesic Use in Older Adults with Back Pain: The BACE Study. Pain Med. 2014, 15, 1704–1714.
[CrossRef]
26. Chou, R.; Huffman, L.H. Medications for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain
Society/American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 2007, 147, 505–514. [CrossRef]
27. Chou, R.; Qaseem, A.; Owens, D.K.; Shekelle, P. Clinical Guidelines Committee of the American College of Physicians. Diagnostic
Imaging for Low Back Pain: Advice for High-Value Health Care from the American College of Physicians. Ann. Intern. Med. 2011,
154, 181–189. [CrossRef] [PubMed]
28. Deyo, R.A.; Smith, D.H.M.; Johnson, E.S.; Donovan, M.; Tillotson, C.J.; Yang, X.; Petrik, A.F.; Dobscha, S.K. Opioids for back pain
patients: Primary care prescribing patterns and use of services. J. Am. Board Fam. Med. 2011, 24, 717–727. [CrossRef]
29. Low back pain and sciatica in over 16s: Assessment and management (NICE guideline NG59) 2016 25.05.2020. Available online:
https://www.nice.org.uk/guidance/ng59 (accessed on 25 March 2021).
30. Stochkendahl, M.J.; Kjaer, P.; Hartvigsen, J.; Kongsted, A.; Aaboe, J.; Andersen, M.; Andersen, M.Ø.; Fournier, G.; Højgaard, B.;
Jensen, M.B.; et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar
radiculopathy. Eur. Spine J. 2018, 27, 60–75. [CrossRef]
31. Mann, E.G.; Johnson, A.; Van Den Kerkhof, E.G. Frequency and characteristics of healthcare visits associated with chronic pain:
Results from a population-based Canadian study. Can. J. Anaesth 2016, 63, 411–441. [CrossRef] [PubMed]
32. Trottmann, M.; Frueh, M.; Telser, H.; Reich, O. Physician drug dispensing in Switzerland: Association on health care expenditures
and utilization. BMC Health Serv. Res. 2016, 16, 238. [CrossRef] [PubMed]
33. van Tulder, M.W.; Touray, T.; Furlan, A.D.; Solway, S.; Bouter, L.M. Muscle Relaxants for Nonspecific Low Back Pain: A Systematic
Review Within the Framework of the Cochrane Collaboration. Spine (Phila Pa 1976) 2003, 28, 1978–1992. [CrossRef] [PubMed]
34. Urquhart, D.M.; Hoving, J.L.; Assendelft, W.W.; Roland, M.; van Tulder, M.W. Antidepressants for non-specific low back pain.
Cochrane Database Syst. Rev. 2008, 2008, Cd001703. [CrossRef]
35. Finan, P.H.; Goodin, B.R.; Smith, M.T. The association of sleep and pain: An update and a path forward. J. Pain 2013, 14, 1539–1552.
[CrossRef] [PubMed]
J. Clin. Med. 2021, 10, 1366 12 of 12
36. Alsaadi, S.M.; McAuley, J.H.; Hush, J.M.; Maher, C.G. Prevalence of sleep disturbance in patients with low back pain. Eur. Spine J.
2011, 20, 737–743. [CrossRef]
37. Lanza, F.L.; Chan, F.K.; Quigley, E.M. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009,
104, 728–738. [PubMed]
38. Schmidt, C.O.; Raspe, H.; Pfingsten, M.; Hasenbring, M.; Basler, H.D.; Eich, W.; Kohlmann, T. Back pain in the German adult
population: Prevalence, severity, and sociodemographic correlates in a multiregional survey. Spine 2007, 32, 2005–2011. [CrossRef]
[PubMed]
39. Raspe, H. Rückenschmerzen. Gesundheitsberichterstattung des Bundes [Internet] 2012 May 2020, 53. Available online: https:
//www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsT/rueckenschmerzen.
pdf?__blob=publicationFile (accessed on 25 March 2021).
